Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention?

Expert Opinion on Biological Therapy
Karin JöhrerTanja N Hartmann

Abstract

Chemokines and their receptors play essential roles in the development, maintenance and proper functioning of the immune system. B cell-T cell interactions are modulated by chemokines. In B cell malignancies, these interactions may have tumor-promoting consequences. This review summarizes physiological B cell-T cell interactions and discusses their pathological role in the onset and progression of B cell malignancies with a special focus on chronic lymphocytic leukemia and multiple myeloma. Experimental data on chemokine-guided B cell-T cell actions in B cell malignancies from murine models as well as in vitro data are summarized and their potential as future therapeutic targets is critically discussed. Direct or indirect targeting of chemokine receptors involved in localization and T-cell-dependent activation of B lymphocytes can provide strong synergisms with conventional or immunomodulatory therapies by disrupting the microenvironmental conditions necessary for survival and proliferation of malignant B lymphocytes. However, further knowledge of these interactions between B and T cells is needed.

References

Jan 1, 1993·The Journal of Experimental Medicine·M BuschleM K Brenner
Jan 31, 1995·Proceedings of the National Academy of Sciences of the United States of America·D M HilbertS Rudikoff
Jan 1, 1994·Annual Review of Immunology·I C MacLennan
Sep 1, 1993·The Journal of Experimental Medicine·A D Luster, P Leder
Apr 1, 1997·Immunological Reviews·Y J Liu, C Arpin
Mar 21, 1998·British Journal of Haematology·N E KayM M Oken
Apr 7, 1998·Immunity·M K SlifkaR Ahmed
Oct 24, 2000·Immunological Reviews·J G CysterV N Ngo
Dec 6, 2000·The Journal of Experimental Medicine·P SchaerliB Moser
Mar 29, 2001·Nature Immunology·M Thelen
May 9, 2001·The Journal of Experimental Medicine·E S BaekkevoldG Haraldsen
Jul 4, 2001·The Journal of Experimental Medicine·D C HargreavesJ G Cyster
Nov 8, 2001·Journal of the National Cancer Institute·H E WileyS T Hwang
Nov 10, 2001·Nature Immunology·R S BystryA G Betz
May 1, 2002·European Journal of Immunology·Paolo GhiaFederico Caligaris-Cappio
Jul 3, 2002·The Journal of Experimental Medicine·Takaharu OkadaJason G Cyster
Jul 23, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anja E HauserRudolf A Manz
Oct 9, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Heather A Minges WolsPamela L Witte
Feb 27, 2003·Immunology·Francesca Di Rosa, Angela Santoni
Mar 19, 2003·Proceedings of the National Academy of Sciences of the United States of America·Kozi IchiyamaNaoki Yamamoto
May 7, 2003·The Journal of Experimental Medicine·Lars OhlReinhold Förster
Sep 27, 2003·Blood·Richard LeBlancNikhil C Munshi
Oct 29, 2003·Cytometry. Part B, Clinical Cytometry·A GallegoA Durántez
Nov 18, 2003·British Journal of Haematology·Federico Caligaris-Cappio
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven M DevineJohn F DiPersio

❮ Previous
Next ❯

Citations

Dec 7, 2013·Journal of Hematology & Oncology·Beatriz Somovilla-CrespoCecilia Muñoz-Calleja
Oct 14, 2014·Expert Opinion on Biological Therapy·Karin JöhrerRichard Greil
Dec 5, 2012·British Journal of Haematology·Caterina MusolinoSebastiano Gangemi
Apr 30, 2021·Saudi Journal of Biological Sciences·Gamal BadrSalman Alamery

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.